Table 2.
Characteristics of patients receiving QT-prolonging drugs
| All patients (n=6125) | QT-prolonging drugs not coadministered (n=4986) | QT-prolonging drugs coadministered (n=1139) | p-value1 | |
|---|---|---|---|---|
| Age (years) (±SE) | 63.0 (±0.2) | 62.8 (±0.20) | 63.5 (±0.5) | 0.474 |
| Gender (% male) | 55.4 | 54.5 | 59.2 | 0.005 |
| Ethnicity (%) | 0.955 | |||
| Caucasian | 84.4 | 84.2 | 85.4 | |
| African American | 8.3 | 8.4 | 8.0 | |
| Latin/Hispanic | 4.5 | 4.6 | 4.3 | |
| Not specified/Other | 2.7 | 2.8 | 2.3 | |
| ICU Mortality Rate (%) | 11.8 | 10.9 | 16.0 | <0.001 |
| ICU LOS (days) (mean±SE) | 8.4 (±0.1) | 7.2 (±0.12) | 13.3 (±0.4) | <0.001 |
| Pre-existing disease (%) | ||||
| Cardiac | 13.2 | 13.8 | 10.5 | 0.004 |
| Respiratory | 10.2 | 10.1 | 10.7 | 0.610 |
| Renal | 3.2 | 3.3 | 2.5 | 0.195 |
| Gastrointestinal | 3.8 | 3.8 | 3.8 | 0.998 |
1
Refers to comparison between patients not receiving and receiving coadministered QT-prolonging drugs